Abstracts

Residual Viremia Caused by Clonally Expanded Tumor-Infiltrating CD4+ Cells

Background: Clonal expansion of infected cells can contribute to HIV-1 persistence. We recently reported that a clonally-expanded population of HIV-infected cells was responsible for persistent viremia despite ART in a patient with metastatic squamous cell carcinoma (Maldarelli, et al., 2014). We conducted extensive ante- and post-mortem analysis of HIV-infected cells from this patient to investigate…

Analysis of HIV RNA in Single Cells Reveals Clonal Expansions and Defective Genomes

Background: Little is known about HIV-1 provirus expression in patients on suppressive ART. Characterizing cell-associated RNA (CAR) sequences in single cells can reveal their relationship to proviral populations and to persistent viremia. Here, we describe a new, sensitive method to assess the genetics of HIV CAR in viremic and virologically suppressed patients. Methods: HIV-1 CAR…

Low-Level HIV Viremias Originate in Part From Infected Proliferating Cells

Background: Understanding mechanisms that allow HIV infection to persist despite suppressive antiretroviral therapy (ART) may help develop cure strategies. We observed that cells with HIV integrated into genes associated with cell proliferation or cancer form persistent clones, defined as multiple cells with identical proviruses (HIV env C2-V5) and with identical integration sites (IS). We hypothesized…

Treatment With a TLR7 Agonist Induces Transient Viremia in SIV-Infected ART-Suppressed Monkeys

Background: Latent reservoirs of replication competent HIV-1 persist in patients on antiretroviral therapy (ART) and represent the major obstacle to HIV eradication efforts. Considerable effort has been directed to identify pharmaceutical agents capable of safely reactivating latent HIV-1 in ART-suppressed patients. Methods: A study was conducted in SIV-infected rhesus macaques (RM) on ART to determine…

Panobinostat Broadly Activates Latent HIV-1 Proviruses in Patients

Background: To target the persistence of quiescent HIV-1 during ART, HDAC inhibitors have been used to induce viral transcription, which could potentially facilitate viral clearance. It is important that all replication competent proviruses are activated to fully purge infection. Therefore, we performed an in-depth analysis of the panobinostat clinical trial to determine whether the observed…

The Size of the Active HIV Reservoir Predicts Timing of Viral Rebound

Background: Strategies to achieve sustained ART-free HIV remission will require validation in analytic treatment interruption (ATI) trials. Identifying virologic biomarkers that can predict time to viral rebound could accelerate the development of such therapeutics. We examined the association of pre-ATI cell-associated RNA (CA-RNA), DNA (CA-DNA), and residual viremia (RV) with timing of viral rebound during…

Biomarkers to Predict Viral Rebound at Antiretroviral Therapy Interruption in SPARTAC

Background: Treatment of HIV-1 infection with antiretroviral therapy (ART) in the first few weeks or months following transmission may induce a state of virological remission or ‘post-treatment control’ (PTC), in which viraemia remains suppressed when ART is stopped. We present an analysis of 18 immunological and virological biomarkers measured in primary HIV-1 infection (PHI) to…

HIV-1 Infections With Multiple Founders Are Associated With Higher Viral Loads

Background: A single HIV-1 genetic variant establishes infection in most subjects, including breakthrough infections in the Step/HVTN-502 and RV144 vaccine efficacy trials. We sought to evaluate whether characteristics of the founder viral populations could influence clinical outcomes in the infected participants, specifically whether subjects infected with multiple founder variants would exhibit higher viral loads or…